Senolytic Therapy Cut Mouse Seizures, Protected One-Third From Epilepsy

A five-fold rise in senescent glial cells marked temporal-lobe tissue from drug-resistant epilepsy patients, Georgetown University Medical Center investigators reported December 22 in Annals of Neurology. In companion experiments, dasatinib plus quercetin halved senescent-cell counts in epileptic mice and protected one-third of treated animals from developing seizures.

The NIH-funded work combined human surgical-tissue analysis with a kainic-acid mouse model of temporal lobe epilepsy, or TLE. Glial cells support and insulate neurons but generate no electrical impulses of their own. Senescent cells have stopped dividing and release inflammatory factors that damage surrounding tissue.

What did the mouse experiments show?

Within two weeks of the inducing brain injury, mice displayed elevated senescence markers at both gene and protein levels. The team intervened with two strategies: a genetic clearance approach and a drug cocktail of dasatinib plus quercetin, abbreviated D+Q.

Senescent-cell burden fell by approximately 50 percent in both arms. Treated mice performed normally on maze-based spatial memory tests and exhibited fewer behavioral seizures. About one-third of D+Q-treated animals never developed epilepsy.

What does this change for clinicians treating drug-resistant patients?

The findings do not alter current scalp EEG, intracranial EEG (iEEG), or magnetoencephalography (MEG) monitoring practice. They do identify senescent glia as a candidate cellular target for the roughly 40 percent of epilepsy patients whose seizures originate in the temporal lobe and resist standard antiseizure medications.

Senior author Patrick A. Forcelli, Ph.D., chair of pharmacology and physiology at Georgetown, framed the translational aim. "A third of individuals living with epilepsy don't achieve freedom from seizures with current medications," he said.

"Our hope is that senotherapy, which involves using medications to remove senescent, or aging cells, could potentially minimize the need for surgery and/or improve outcomes after surgery."

Why dasatinib and quercetin?

Dasatinib carries FDA approval for Philadelphia-chromosome-positive chronic myeloid leukemia, a blood cancer driven by a chromosomal swap between chromosomes 9 and 22. Its safety profile in humans is well characterized. Quercetin is a plant flavonoid — a pigmented polyphenol common in fruits, vegetables, tea, and wine — with documented antioxidant and anti-inflammatory activity.

Both agents have entered early-phase human trials for non-epilepsy indications. Forcelli noted that this prior clinical exposure could compress the regulatory timeline to a first epilepsy study in people.

What remains unproven?

Human evidence is descriptive and limited to banked surgical specimens. No human electrophysiology was performed. In the mouse arm, seizure outcomes were scored by behavioral observation rather than continuous video-EEG telemetry, in which concurrent video and electrical recording allow precise seizure counting. That methodological gap is the first item the field will scrutinize.

What comes next?

Forcelli said the laboratory is extending the work to other rodent epilepsy models and additional senolytic candidates, defined as compounds that selectively kill senescent cells. The group aims to map intervention windows — the time intervals after an epileptogenic injury during which senescent-cell clearance remains effective.

"We have ongoing studies using other repurposed drugs that can impact senescence as well as studies in other rodent models of epilepsy," Forcelli said. "We would like to understand the critical windows for intervention in epilepsy, and the hope is that these studies will lead to clinically useful treatments."

First co-authors Tahiyana Khan, Ph.D., and David J. McFall, both trainees in Forcelli's lab, have separately linked glial senescence to normal aging and to Alzheimer's disease. Whether senolytic therapy translates from mouse TLE to human drug-resistant epilepsy is the practical question every epilepsy monitoring unit will now be watching.